Work

Nivolumab/ipilimumab with or without CBM588 in metastatic renal cell carcinoma: A randomized phase Ib study and the evolution of the functionality of microbial communities with treatment.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.6_suppl.371

Authors: Nazli Dizman, Luis A Meza, Paulo Gustavo Bergerot, Marice Alcantara, Tanya B. Dorff, Yung Lyou, Paul Henry Frankel, Marian Llamas, Joann Hsu, Zeynep Busra Zengin, Jasnoor Malhotra, John D Gillece, Lauren J Reining, Jeffrey M. Trent, Motomichi Takahashi, Kentaro Oka, Seiya Higashi, Sarah K Highlander, Sumanta K. Pal

Institutions: City Of Hope National Medical Center, University of California, Irvine, City of Hope, Translational Genomics Research Institute, Miyarisan Pharmaceutical Co., Ltd. (Japan)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Gateway Foundation

OpenAlex ID: W4212770169

Cites:

Cited by:

Related to: 10